Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 306, Issue 4, 2014, Pages

  Ganji, Shobha H ^a,b   Kukes, Gary D ^a,b   Lambrecht, Nils ^a,b   Kashyap, Moti L ^a,b   Kamanna, Vaijinath S ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatic steatosis; Niacin; Nicotinic acid; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

HEPATIC STEATOSIS; NIACIN; NICOTINIC ACID; NONALCOHOLIC FATTY LIVER DISEASE; NONALCOHOLIC STEATOHEPATITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INFLAMMATION MEDIATORS; LIPID METABOLISM; LIPID PEROXIDATION; LIVER; MALE; NIACIN; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TIME FACTORS; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84894213660     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00181.2013     Document Type: Article

References (39)

1. Abdelmalek MF, Diehl AM. Nonalocoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 91: 1125-1149, 2007.
2. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 82: 315-322, 2006.
3. Ahmed MH, Byrne CD. Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 11: 188-195, 2009.
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
5. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87: 1-16, 2006.
6. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. N Engl J Med 355: 2297-2307, 2006.
7. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96: 519-525, 2001.
8. Carlson LA. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand 173: 719-722, 1963.
9. Carmiel-Haggai M, Cederbaum AI, Nieto N. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 19: 136-138, 2005.
10. Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K, Kim S, Distefano A, Samuel VT, Neschen S, Zhang D, Wang A, Zhang XM, Kahn M, Cline GW, Pandey SK, Geisler JG, Bhanot S, Monia BP, Shulman GI. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverse diet-induced hepatic steatosis and insulin resistance. J Biol Chem 282: 22678-22688, 2007.
11. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 122: 1649-1657, 2002.
12. Day CP, James OF. Hepatic steatosis: Innocent bystander or guilty party? Hepatology 27: 1463-1466, 1998.
13. Day CP, James OF. Steatohepatitis: a tale of two "hit"? Gastroenterology 114: 842-845, 1998.
14. Deng QG, She H, Cheng JH, French SW, Koop DR, Xiong S, Tsukamoto H. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 42: 905-914, 2005.
15. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185, 2003.
16. Fabbrini E, Mohammed BS, Korenblat KM, Magkos F, McCrea J, Patterson BW, Klein S. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very-low density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 95: 2727-2735, 2010.
17. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 202: 68-75, 2009.
18. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. Niacin non-competitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 45: 1835-1845, 2004.
19. Harrison SA, Torgerson S, HayashiP, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98: 2485-2490, 2003.
20. Hernandez M, Wright SD, Cai TQ. Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochem Biophys Res Commun 355: 1075-1080, 2007.
21. Hu M, Chu WC, Yamshita S, Yeung DK, Shi L, Wang D, Masuda D, Yang Y, Tomlinson B. Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients. J Lipid Res 53: 802-809, 2012.
22. Jin YJ, Kim KM, Hwang S, Lee SG, Ha TY, Song GW, Jung DH, Kim KH, Yu E, Shim JH, Lim YS, Lee HC, Chung YH, Lee Y, Suh DJ. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: Analysis of biopsies of living liver donors. J Gastroenterol Hepatol 27: 1341-1347, 2012.
23. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 101: 20B-26B, 2008.
24. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 136: 734-738, 2000.
25. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo clinic experience with a hitherto unnamed disease. Mayo Clin Proc 5: 434-438, 1980.
26. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 15: 659-665, 2004.
27. Misra VL, Khashab M, Chalasani N. Non-alcoholic fatty liver disease and cardiovascular risk. Curr Opin Gastroenterol Rep 11: 50-55, 2009.
28. Monetti M, Levin MC, Watt MJ, Sajan MP, Marmor S, Hubbard BK, Stevens RD, Bain JR, Newgard CB, Farese RV Sr, Hevener AL, Farese RV Jr. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 6: 69-78, 2007.
29. Morgan K, Uyuni A, Nandgiri G, Mao L, Castaneda L, Kathirvel E, French SW, Morgan TR. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 20: 843-854, 2008.
30. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38: 1008-1017, 2003.
31. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35: 367-372, 2002.
32. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118: 829-838, 2008.
33. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279: 32345-32353, 2004.
34. Sanyal A, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362: 1675-1685, 2010.
35. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Clore J, Mills AS. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenerol Hepatol 2: 1107-1115, 2004.
36. Schattenberg JM, Galle PR. Animal models of non-alcoholic steatohepatitis: of mice and man. Dig Dis 28: 247-254, 2010.
37. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27: 103-107, 1997.
38. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12: 1106-1110, 1990.
39. Yu XX, Murray SF, Pandey SK, Booten SL, Bao D, Song XZ, Kelly S, Chen S, McKay R, Monia BP, Bhanot S. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42: 362-371, 2005.